加载中
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
前收盘价
US$0.4053
−US$0.0418 · -9.35%
盘中时间采用ET。市场数据可能有所延迟。
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
日内区间
当前US$0.4053
52周区间
当前US$0.4053
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
强力卖出
估值
11
估值过高
情绪
44
多空交织
风险
82
极高风险
动量
23
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
日内区间
当前US$0.4053
52周区间
当前US$0.4053
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 203.8万 USD | — | — | 156.5万 USD | 126.3万 USD |
| 销货成本 | 1704.7万 USD | 719万 USD | 7655万 USD | 825.5万 USD | 6134.1万 USD |
| 毛利 | −1500.9万 USD | −719万 USD | −7655万 USD | −669万 USD | −6007.8万 USD |
| 研究与开发 | 6930.2万 USD | 8859.9万 USD | 7655万 USD | 6326万 USD | 6134.1万 USD |
| 销售、一般及管理费用 | 3117.1万 USD | 2579.9万 USD | 2039万 USD | 2288.3万 USD | 2113万 USD |
| 营业费用 | 9242.8万 USD | 1.07亿 USD | 2349.7万 USD | 7788.8万 USD | 2113万 USD |
| 利息收入 | 258.7万 USD | 410.4万 USD | 546.7万 USD | 262.9万 USD | 1.6万 USD |
| 利息支出 | 1125万 USD | 927.7万 USD | 659.9万 USD | 620万 USD | 434.8万 USD |
| 折旧和摊销 | 734.5万 USD | 719万 USD | 771.9万 USD | 821万 USD | 824.1万 USD |
| 营业利润 | −1.07亿 USD | −1.14亿 USD | −1亿 USD | −8457.8万 USD | −8120.8万 USD |
| 净利润 | −4083.3万 USD | −1.49亿 USD | −1.11亿 USD | −1196.5万 USD | −2647.7万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.00
上涨空间 393.46%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI464.09万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF127.67万0.00%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB85.18万0.01%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA60.44万0.00%218.24亿 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT46.11万0.00%220亿 USD0.09%US$319.01+1.64%
Invesco RAFI US 1500 Small-Mid ETFPRFZ17.31万0.01%26.7亿 USD0.36%US$53.16+0.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6万0.05%1.17亿 USD0.73%US$15.9402+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ8377.550.01%1.12亿 USD0.19%US$34.62+2.96%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco Nasdaq Biotechnology ETFIBBQAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
